Sun, Sep 21, 2014, 10:53 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Human Genome Sciences Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • vs1234gs vs1234gs Sep 20, 2011 10:36 AM Flag

    Some Benlysta Patients Forum links

    Total Phase II patient 449
    At 52 week - 345 (22% drop out) continue (All switch to Benlysta including placebo for another 24 Week)
    At 76 Week - 296 choose to continue for long term trial (All Switch to 10mg/KG) (only 15% drop out)
    213 continue to receive it as of June 1. So On average nearly 50% continue on trial after enrolling to start. Remmeber this is clinical trial which has additional requirement and many drop out even it help them little bit. I am sure who see most benefit will try remain as long as possible.

    http://www.hgsi.com/latest/human-genome-sciences-reports-positive-long-term-data-for-benlysta-formerly-lymphostat-b-in-patients-with-active-systemic-lupus-erythema-8.html
    It's patient with atleast 4 year on Benlysta result. Who ever claim including Analyst that it stop working after 52 are not reading trial result because they are nearly as good as Phase III 52 Week result. There is no Placebo compare so you can't tell whether they much better than placebo.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • none of these results matter. The company is unsuccessful selling the drug and the size of the Lupus Market has been overstated by a factor of 10. So the future revenues of the company-the true factor of a companys worth-will never be what it once was. This is the reason why HGSI will be heading to the single digits. Its just a matter of time before the next earnings release reveals how small this market is.

      • 1 Reply to triceptorman
      • Best of Luck. Looking into Forums and compare it with Other Medical condition, I don't think they mis-calcuated number (Unless Lupus patient more pro-active). GSK/HGSI do research on how many average Lupus patient on those 2000 Accounts , it's 100+/account or 200K+. I think 30-40% by 2015 is very likely. So US Revenue alone will be $2B+.

 

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.